Clinical characteristics and treatment modalities in uremic and non uremic calciphylaxis - a dermatological single-center experience

References

• Brandenburg VM, Kramann R, Rothe H, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017;32(1):1–10.
   PubMed Web of Science ®Google Scholar
• Perelló J, Joubert PH, Ferrer MD, et al. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. Br J Clin Pharmacol. 2018;84(12):2867–2876. doi: 10.1111/bcp.13752.
   PubMed Web of Science ®Google Scholar
• Weenig RH, Sewell LD, Davis MDP, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569–579. doi: 10.1016/j.jaad.2006.08.065.
   PubMed Web of Science ®Google Scholar
• Strehl JD, Brandenburg V, Forster C, et al. Kalziphylaxie : Ein wenig bekanntes, klinisch relevantes krankheitsbild. Pathologe. 2011;32(3):250–256. doi: 10.1007/s00292-010-1411-1.
   PubMedGoogle Scholar
• Ellis CL, O’Neill WC. Questionable specificity of histologic findings in calcific uremic arteriolopathy. Kidney Int. 2018;94(2):390–395. doi: 10.1016/j.kint.2018.03.016.
   PubMed Web of Science ®Google Scholar
• Mochel MC, Arakaki RY, Wang G, et al. Cutaneous calciphylaxis: a retrospective histopathologic evaluation [Internet]. 2013. Available from: www.amjdermatopathology.com.
   Google Scholar
• Nigwekar SU, Wolf M, Sterns RH, et al. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3(4):1139–1143. Jul doi: 10.2215/CJN.00530108.
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Evenepoel P, Floege J, et al. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant. 2016;31(8):1211–1219. 1 doi: 10.1093/ndt/gfw025.
   PubMed Web of Science ®Google Scholar
• Erfurt-Berge C, Renner R. Management of patients with calciphylaxis: current perspectives. CWCMR. 2019; 6:109–115. doi: 10.2147/CWCMR.S182417.
   Google Scholar
• Cucchiari D, Torregrosa JV. Calcifilaxis en pacientes con enfermedad renal crónica: una enfermedad todavía ­desconcertante y potencialmente mortal. Nefrología. 2018; 38(6):579–586. doi: 10.1016/j.nefro.2018.05.007.
   PubMedGoogle Scholar
• Yu WYH, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017;153(3):309–314. doi: 10.1001/jamadermatol.2016.4821.
   PubMed Web of Science ®Google Scholar
• May J, Kuschel S, Tsoukas MM. Warfarin-induced nonuremic calciphylaxis: a case study and overview book ­review view project [Internet]. Available from: https://www.researchgate.net/publication/369020599.
   Google Scholar
• Gallo Marin B, Aghagoli G, Hu SL, et al. Calciphylaxis and kidney disease: a review. Am J Kidney Dis. 2023;81(2):232–239. doi: 10.1053/j.ajkd.2022.06.011.
   PubMed Web of Science ®Google Scholar
• Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210–2217. doi: 10.1046/j.1523-1755.2002.00375.x.
   PubMed Web of Science ®Google Scholar
• Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage ­renal disease. Kidney Int. 2001;60(1):324–332. doi: 10.1046/j.1523-1755.2001.00803.x.
   PubMed Web of Science ®Google Scholar
• Guzmán UV, De La Cueva P, Verde E, et al. Calciphylaxis: fatal complication of cardio-metabolic syndrome in ­patients with end stage kidney disease [Internet]. 2008 1. Available from: http://www.senefro.org.
   Google Scholar
• Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580–1584. doi: 10.1093/ndt/gfr658.
   PubMed Web of Science ®Google Scholar
• Fernández M, Morales E, Gutierrez E, et al. Calciphylaxis: beyond CKD-MBD. Nefrologia. 2017;37(5):501–507. 1doi: 10.1016/j.nefroe.2017.09.003.
   PubMed Web of Science ®Google Scholar
• Gaisne R, Péré M, Menoyo V, et al. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. BMC Nephrol. 2020;21(1):63. Feb 26 doi: 10.1186/s12882-020-01722-y.
   PubMed Web of Science ®Google Scholar
• Ahmed S, O[rsquo ]Neill KD, Hood AF, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. American Journal of Kidney Diseases. 2001;37(6):1267–1276. doi: 10.1053/ajkd.2001.24533.
   PubMed Web of Science ®Google Scholar
• Hafner J, Nobbe S, Partsch H, et al. Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. Arch Dermatol. 2010;146(9):961–968. doi: 10.1001/archdermatol.2010.224.
   PubMedGoogle Scholar
• Gomes FM, La Feria P, Costa C, et al. Non-Uremic calciphylaxis: a rare diagnosis with limited therapeutic strategies. Eur J Case Rep Intern Med. 2018;5(12):000986.4 doi: 10.12890/2018_000986.
   PubMedGoogle Scholar
• Angelis M, Wong LL, Myers SA, et al. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122(6):1083–1090. doi: 10.1016/s0039-6060(97)90212-9.
   PubMed Web of Science ®Google Scholar
• Roy R, Lee JA. Calciphylaxis due to hyperparathyroidism. Endocr Pract:. 2011;17(Suppl 1):54–56. doi: 10.4158/EP10349.RA.
   PubMedGoogle Scholar
• Bleyer AJ, Choi M, Igwemezie B, et al. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32(3):376–383. doi: 10.1053/ajkd.1998.v32.pm9740152.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Brandenburg V, Jahnen-Dechent W, et al. Do not be misguided by guidelines: the calcium x phosphate product can be a trojan horse. Nephrol Dial Transplant. 2005;20(4):673–677. doi: 10.1093/ndt/gfh734.
   PubMed Web of Science ®Google Scholar
• Santos PW, He J, Tuffaha A, et al. Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy. Int Urol Nephrol. 2017;49(12):2247–2256. doi: 10.1007/s11255-017-1721-9.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang C, Yang X, et al. Prevalence and clinical characteristics of calciphylaxis in Chinese hemodialysis ­patients. Front Med. 2022;9:902171. doi: 10.3389/fmed.2022.902171.
   Web of Science ®Google Scholar
• Zhang L, Zhao Y, Guo Z, et al. Does serum calcium level play a practical role in calciphylaxis in hemodialysis patients? Ren Fail. 2021;43(1):1506–1507. doi: 10.1080/0886022X.2021.1999828.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Xie X, et al. Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study. Ren Fail. 2021;43(1):406–416.
   PubMed Web of Science ®Google Scholar
• Oliveira TM, Frazão JM. Calciphylaxis: from the disease to the diseased. J Nephrol. 2015;28(5):531–540. doi: 10.1007/s40620-015-0192-2.
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013;37(4):325–332. Apr doi: 10.1159/000348806.
   PubMed Web of Science ®Google Scholar
• Eiser AR. Warfarin, calciphylaxis, atrial fibrillation, and patients on dialysis: outlier subsets and practice guidelines. Am J Med. 2014;127(4):253–254. doi: 10.1016/j.amjmed.2013.08.033.
   PubMed Web of Science ®Google Scholar
• Holden RM, Clase CM. Use of warfarin in people with low glomerular filtration rate or on dialysis. Semin Dial. 2009;22(5):503–511. doi: 10.1111/j.1525-139X.2009.00632.x.
   PubMed Web of Science ®Google Scholar
• Schurgers LJ, Cranenburg ECM, Vermeer C. Matrix gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008;100(4):593–603. doi: 10.1160/TH08-02-0087.
   PubMed Web of Science ®Google Scholar
• Lehman JS, Chen TY, Lohse CM, et al. Evaluating the validity of subclassifying warfarin-associated nonuremic calciphylaxis: a retrospective cohort study. Int J Dermatol. 2018;57(5):572–574. doi: 10.1111/ijd.13884.
   PubMed Web of Science ®Google Scholar
• Chan KE, Michael Lazarus J, Thadhani R, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223–2233. doi: 10.1681/ASN.2009030319.
   PubMed Web of Science ®Google Scholar
• Bennett WM. Should dialysis patients ever receive warfarin and for what reasons? Clin J Am Soc Nephrol. 2006;1(6):1357–1359. doi: 10.2215/CJN.01700506.
   PubMed Web of Science ®Google Scholar
• Garza-Mayers AC, Shah R, Sykes DB, et al. The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: a retrospective analysis. Am J Nephrol. 2018;48(3):168–171. doi: 10.1159/000491881.
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Brunelli SM, Meade D, et al. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am SocNephrol. 2013;8(7):1162–1170. doi: 10.2215/CJN.09880912.
   PubMed Web of Science ®Google Scholar
• Zitt E, Konig M, Vychytil A, et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant. 2013;28(5):1232–1240. doi: 10.1093/ndt/gfs548.
   PubMed Web of Science ®Google Scholar
• Cicone JS, Petronis JB, Embert CD, et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43(6):1104–1108. doi: 10.1053/j.ajkd.2004.03.018.
   PubMed Web of Science ®Google Scholar
• Iwagami M, Mochida Y, Ishioka K, et al. LDL-apheresis dramatically improves generalized calciphylaxis in a patient undergoing hemodialysis. Clin Nephrol. 2014;81(3):198–202.
   PubMed Web of Science ®Google Scholar
• Levy R. Potential treatment of calciphylaxis with vitamin K 2: comment on the article by Jacobs-Kosmin and DeHoratius. Arthritis Rheumatism. 2007;57(8):1575–1576. doi: 10.1002/art.23107.
   PubMedGoogle Scholar
• Wajih Z, Singer R. Successful treatment of calciphylaxis with vitamin K in a patient on haemodialysis. Clin Kidney J. 2022;15(2):354–356.
   PubMed Web of Science ®Google Scholar
• Cañabate SF, Alvarez CL, Valin LO, et al. Sodium thiosulfate and pamidronate for treatment of calciphylaxis: case report. Colomb Med. 2018;49(4):288–291.
   Web of Science ®Google Scholar
• Schliep S, Schuler G, Kiesewetter F. Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol. 2008;18(5):554–556.
   PubMed Web of Science ®Google Scholar
• Latus J, Kimmel M, Ott G, et al. Early stages of calciphylaxis: Are skin biopsies the answer? Case Rep Dermatol. 2011;3(3):201–205. doi: 10.1159/000333007.
   PubMedGoogle Scholar
• Wen W, Portales-Castillo I, Seethapathy R, et al. Intravenous sodium thiosulphate for calciphylaxis of chronic kidney disease: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(4):e2310068. doi: 10.1001/jamanetworkopen.2023.10068.
   PubMed Web of Science ®Google Scholar
• Yang X, Liu Y, Xie X, et al. Use of the optimized sodium thiosulfate regimen for the treatment of calciphylaxis in Chinese patients. Ren Fail. 2022;44(1):914–922.
   PubMed Web of Science ®Google Scholar
• Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy [5]. Arch Dermatol. 2007;143(2):269–270. doi: 10.1001/archderm.143.2.269.
   PubMedGoogle Scholar
• Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol. 1985;23(2):63–67.
   PubMed Web of Science ®Google Scholar
• Generali JA, Cada DJ. Off-label drug uses: sodium thiosulfate: calciphylaxis. Hosp Pharm. 2015;50(11):975–977. doi: 10.1310/hpj5011-975.
   PubMedGoogle Scholar
• Mao M, Lee S, Kashani K, et al. Severe anion gap acidosis associated with intravenous sodium thiosulfate administration. J Med Toxicol. 2013;9(3):274–277. doi: 10.1007/s13181-013-0305-z.
   PubMedGoogle Scholar
• Selk N, Rodby RA. Unexpectedly severe metabolic acidosis associated with sodium thiosulfate therapy in a patient with calcific uremic arteriolopathy. Semin Dial. 2011;24(1):85–88.
   PubMed Web of Science ®Google Scholar
• Hooman N, Naghshi-Zadiyan R, Mehrazma M, et al. Successful treatment of calciphylaxis with pamidronate. Iran J Kidney Dis. 2015;9(1):67–70.
   PubMed Web of Science ®Google Scholar
• Monney P, Nguyen QV, Perroud H, et al. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant. 2004;19(8):2130–2132. doi: 10.1093/ndt/gfh305.
   PubMed Web of Science ®Google Scholar
• Truong DH, Riedhammer MM, Zinszer K. Non-uraemic calciphylaxis successfully treated with pamidronate infusion. Int Wound J. 2019;16(1):250–255. doi: 10.1111/iwj.13019.
   PubMed Web of Science ®Google Scholar
• Deen J, Schaider H. The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: a comprehensive review. Aust J Dermatol. 2019;60(3):e186–e194. doi: 10.1111/ajd.12992.
   Web of Science ®Google Scholar
• Chan MR, Ghandour F, Murali NS, et al. Pilot study of the effect of lanthanum carbonate (fosrenol®) In patients with calciphylaxis: a Wisconsin network for health research (WiNHR) study. J Nephrol Ther. 2014;4(3):1000162. doi: 10.4172/2161-0959.1000162.
   PubMedGoogle Scholar
• Wang NN, Qin LJ, Liu K, et al. Multidisciplinary regenerative treatment and mechanisms for rescuing a severe calciphylaxis patient with human amnion-derived mesenchymal stem cells. Zhonghua Yi Xue Za Zhi. 2022;102(28):2217–2221.
   PubMedGoogle Scholar